Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Wockhardt Q1 net loss...

    Wockhardt Q1 net loss shrinks to Rs 45 crore from previous fiscal loss of Rs 89.18 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-18T09:30:58+05:30  |  Updated On 18 Aug 2019 9:30 AM IST
    Wockhardt Q1 net loss shrinks to Rs 45 crore from previous fiscal loss of Rs 89.18 crore

    Total income of the company stood at Rs 871.19 crore during the quarter under review, down 14.18 per cent, from Rs 1,015.14 crore reported in the corresponding period of the previous fiscal, Wockhardt said in a BSE filing.


    New Delhi: Pharmaceutical firm Wockhardt NSE -2.29 % on Wednesday reported narrowing of its consolidated net loss to Rs 44.98 crore for the quarter ended June 30, 2019.


    The company had posted a net loss of Rs 89.18 crore in the same period a year ago.


    Total income of the company stood at Rs 871.19 crore during the quarter under review, down 14.18 per cent, from Rs 1,015.14 crore reported in the corresponding period of the previous fiscal, Wockhardt said in a BSE filing.


    Read Also: Wockhardt new antibiotics under development to have positive impact in future, says founder Khorakiwala


    The company said, during the quarter, it repaid Rs 351 crore towards various long-term debt obligations.


    Total long-term outstanding debts on June 30, 2019, stood at Rs 2,119 crore compared to Rs 2,723 crore as on June 30, 2018, the company added.


    Read Also: Wockhardt gets zero observations from USFDA for bioequivalence centre at Aurangabad

    bse filingFY20FY219June quarterpharmapharma companyPharma Firmpharma newspharma news indiaQ1Wockhardtwockhardt debtwockhardt financial resultswockhardt loss
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok